Home » Stocks » GOVX

GeoVax Labs, Inc. (GOVX)

Stock Price: $5.10 USD -0.30 (-5.56%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $5.09 -0.01 (-0.20%) Feb 26, 5:36 PM
Market Cap 30.81M
Revenue (ttm) 1.84M
Net Income (ttm) -2.21M
Shares Out 782,978
EPS (ttm) -5.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $5.10
Previous Close $5.40
Change ($) -0.30
Change (%) -5.56%
Day's Open 5.34
Day's Range 4.95 - 5.40
Day's Volume 361,985
52-Week Range 2.56 - 8.71

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 1 month ago

GeoVax (NASDAQ: GOVX) shares are trading sharply higher on Monday after the company announced it was awarded an NIH grant to advance its COVID-19 vaccine development. GeoVax is a U.S.-based cl...

GlobeNewsWire - 1 month ago

Company Focused on Single-dose Vaccine Against Multiple COVID Strains

GlobeNewsWire - 1 month ago

GeoVax Also Participating in BIO@JPM During “J.P. Morgan Week 2021”

Seeking Alpha - 3 months ago

GeoVax Labs, Inc. (GOVX) CEO David Dodd on Q4 2020 Results - Earnings Call Transcript

Seeking Alpha - 3 months ago

GeoVax Labs, Inc.'s (GOVX) CEO David Dodd on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

Public Offering Completed in September 2020 Provides Resources to Accelerate COVID-19 Vaccine and Immuno-Oncology Programs

GlobeNewsWire - 3 months ago

Conference call to be held Friday, November 6, at 8:15 a.m. Eastern Time

GlobeNewsWire - 3 months ago

ATLANTA, GA, Oct. 28, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapi...

InvestorPlace - 4 months ago

GeoVax Labs (GOVX) news for Monday includes a deal with the National Institutes of Health to develop a vaccine for the novel coronavirus. The post GeoVax Labs News: GOVX Stock Flies 18% on NIH...

Market Watch - 4 months ago

Shares of GeoVax Labs Inc. were up 12.8% in trading on Monday after the company announced a patent and material licensing deal with the National Institutes of Health for COVID-19 vaccine devel...

GlobeNewsWire - 4 months ago

ATLANTA, GA, Oct. 26, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapie...

GlobeNewsWire - 4 months ago

ATLANTA, GA, Sept. 29, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunothe...

GlobeNewsWire - 5 months ago

ATLANTA, GA, Sept. 24, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunoth...

About GOVX

GeoVax Labs, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has ... [Read more...]

Industry
Biotechnology
Founded
2001
CEO
David Dodd
Employees
6
Stock Exchange
NASDAQ
Ticker Symbol
GOVX
Full Company Profile

Financial Performance

In 2019, GeoVax Labs's revenue was $1.18 million, an increase of 22.08% compared to the previous year's $963,203. Losses were -$2.37 million, -7.40% less than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for GeoVax Labs stock is "Buy" and the 12-month stock price forecast is 8.00.

Price Target
$8.00
Analyst Consensus: Buy